Back close

Tadalafil: A new role in Raynaud’s phenomenon?

Publication Type : Journal Article

Publisher : International Journal of Clinical Rheumatology

Source : International Journal of Clinical Rheumatology, Volume 6, Number 2, p.115-117 (2011)

Url :

Keywords : angiotensin 2 receptor antagonist, bleomycin, bosentan, calcium channel blocking agent, continuous infusion, digital ulcer, dipeptidyl carboxypeptidase inhibitor, drug dosage form comparison, drug efficacy, drug half life, drug mechanism, drug safety, drug tolerability, erectile dysfunction, human, iloprost, ischemia, outcome assessment, patient compliance, phosphodiesterase inhibitor, phosphodiesterase V, placebo, priority journal, prostacyclin, prostacyclin derivative, pulmonary hypertension, quality of life, Raynaud phenomenon, review, scleroderma, sildenafil, skin ulcer, systemic sclerosis, tadalafil, ulcer, vasoconstriction, vasodilator agent

Campus : Kochi

School : School of Medicine

Department : General Medicine

Year : 2011

Abstract : Raynaud’s phenomenon (RP) is an exaggerated physiological phenomenon defined as episodic cold-triggered ischemic vasospasms of the digital arteries and precapillary arterioles. It can be idiopathic or may be a manifestation of underlying connective tissue diseases (CTDs) such as systemic lupus erythematosus, progressive systemic sclerosis (PSS; scleroderma), mixed connective tissue disease or rheumatoid arthritis. RP associated with CTDs is known as secondary RP [1]. It is more severe and causes tissue ischemia, resulting in digital ulcers (DUs). These DUs are often painful and cause progressive digital shortening with significant impairment of hand function and activities of daily living. DUs are a frequent complication in patients with PSS, with an estimated frequency of 17–30% [2].

Cite this Research Publication : P. Da Shenoy and Agarwal, Vb, “Tadalafil: A new role in Raynaud's phenomenon?”, International Journal of Clinical Rheumatology, vol. 6, pp. 115-117, 2011.

Admissions Apply Now